Profitability Ratios
| Ratio |
Value |
| GP Margin |
88.5% |
| EBIT Margin |
41.9% |
| EBITDA Margin |
45.1% |
| Operating Margin |
37.1% |
| Pretax Margin |
40.3% |
| Cont. Ops Margin |
101.5% |
| Net Margin |
101.5% |
| Bottom Line Margin |
101.5% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
5.25 |
| Quick Ratio |
4.76 |
| Solvency Ratio |
1.741 |
| Cash Ratio |
0.86 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.00 |
| Forward PEG |
0.00 |
| Price/Book |
3.69 |
| Price/Sales |
7.57 |
| Price/FCF |
15.83 |
| Price/Op Cash Flow |
15.80 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.0995 |
| Debt/Equity |
0.1287 |
| Debt/Capital |
0.1140 |
| Long-Term Debt/Capital |
0.0896 |
| Financial Leverage |
1.29 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.76 |
| Operating Cash Flow Ratio |
1.447 |
| Operating Cash Flow/Sales |
47.9% |
| Free Cash Flow/Operating Cash Flow |
99.8% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
13.72 |
| Interest Coverage |
24.2296 |
| Short-Term Operating Cash Flow Coverage |
7.71 |
| Operating Cash Flow Coverage |
1.81 |
| Capital Expenditure Coverage |
538.33 |
| Dividend + Capital Expenditure Coverage |
538.33 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
2.11 |
| EPS |
2.137 |
| Debt/Share |
0.5890 |
| Cash/Share |
2.96 |
| Book Value/Share |
4.33 |
| Tangible BV/Share |
4.30 |
| Equity/Share |
4.33 |
| Operating Cash Flow/Share |
1.010 |
| Capital Expenditure/Share |
0.002 |
| FCF/Share |
1.008 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
2.516 |
| Earnings Before Tax/EBIT |
1.088 |
| Price/Fair Value |
3.69 |
| Debt/Market Cap |
0.0349 |
| Effective Tax Rate |
-151.6% |
| Enterprise Value Multiple |
16.73 |
AUPH - Aurinia Pharmaceuticals Inc.